Health Insurance – Bulk Purchasing Pools for Prescription Drugs
HB0088 would authorize certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations to join bulk purchasing pools for prescription drugs. The bill applies to entities that provide prescription drug coverage under individual, group, blanket, or HMO contracts issued or delivered in the state, including coverage administered through a pharmacy benefits manager.
The measure is narrowly focused on permitting these covered entities to participate in collective purchasing arrangements for prescription drugs, presumably to improve bargaining power and lower drug acquisition costs. It does not itself mandate participation in a pool or set pricing rules; rather, it creates express statutory authority for eligible carriers to join such pools beginning October 1, 2026.
HB0088 would add a new section to the Insurance Article, Section 15-128, creating explicit authority for specified insurers, nonprofit health service plans, and HMOs to participate in bulk purchasing pools for prescription drugs. This would affect health insurance carriers and related pharmacy benefits arrangements by clarifying that collective purchasing is permitted under Maryland law for prescription drug coverage. The bill does not appear to change benefit mandates, regulate drug prices directly, or impose new obligations on consumers or providers beyond the authorization itself.
The available record shows no committee testimony or recorded votes, and the bill was ultimately withdrawn by the sponsor in the House. Based on the bill text alone, the proposal appears pragmatic and cost-focused, with an implied goal of reducing prescription drug costs through pooled purchasing. Because there is no recorded floor or committee debate, there is no documented public split in the available materials, and the overall sentiment cannot be assessed beyond the fact that the sponsor chose not to move it forward.
No specific points of contention are documented in the available transcripts or votes. Potential areas of concern, based on the subject matter, could include how bulk purchasing pools would interact with existing pharmacy benefits manager arrangements, whether collective purchasing could affect market competition, and whether the authorization would actually translate into lower premiums or out-of-pocket costs. However, these issues are not explicitly raised in the provided legislative history.